Results 61 to 70 of about 17,677 (210)

Predicting acute decompensated heart failure using circadian markers from heart rate time series

ESC Heart Failure, EarlyView.
Circadian metrics—amplitude, mesor, and acrophase—derived from a wrist‐worn heart rate monitor can predict acute decompensated heart failure (ADHF) up to 21 days before onset. In 65 post‐ADHF patients, an LSTM model achieved 74% sensitivity, and 73% specificity trained on 21‐day sequences. These findings support circadian rhythm analysis as a promising
Valerie A. A. van Es, Mayke M. C. J. van Leunen, Ignace L. J. de Lathauwer, Cindy C. A. G. Verstappen, René A. Tio, Ruud F. Spee, Lu Yuan, Monica Betta, Giacomo Handjaras, Hareld M. C. Kemps   +9 more
wiley   +1 more source

Torasemide – loop diuretic with specific effects

Кардиоваскулярная терапия и профилактика, 2006
A loop diuretic torasemide is characterized by high bioavailability and prolonged action, explaining some beneficial pharmacodynamic features of the medication.
V. M. Gorbunov, R. G. Oganov
doaj  

Subcutaneous Furosemide Therapy for Chronic Management of Refractory Congestive Heart Failure in Dogs and Cats

Animals
Reduced efficacy of oral diuretics in the treatment of congestive heart failure (CHF) can be secondary to reduced enteral drug absorption. The aim of this study was to determine the efficacy of subcutaneous (SC) furosemide administration to control the ...
Sergio F. Lombardo, Heidi Ferasin, Luca Ferasin   +2 more
doaj   +1 more source

Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL‐HF

ESC Heart Failure, EarlyView.
Abstract Aims The EMAIL‐HF trial aims to evaluate whether a digital guideline implementation strategy can increase and accelerate initiation of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and results EMAIL‐HF is a pragmatic, registry‐based, randomized controlled trial including patients with a ...
Mariam Elmegaard, Lars Køber, Mads Kristian Ersbøll, Theis Lange, Christian Ditlev Tuxen, Mette Rauhe Mouridsen, Trine Kiilerich Lauridsen, Jens Jakob Thune, Peter Godsk Jørgensen, Morten Lamberts, Nadia Paarup Dridi, Peter Bonfils, Morten Petersen, Nis Ottesen Stride, Anders Barasa, Jesper Jensen, Caroline Garred, Emil Fosbøl, Emil Wolsk, John McMurray, Mark Petrie, Morten Schou   +21 more
wiley   +1 more source

A 2018 overview of diuretic resistance in heart failure

Revista Portuguesa de Cardiologia, 2018
Heart failure is a disease with high direct and indirect costs. Current treatment includes drugs that alter disease progression and drugs that to improve symptoms.
Sofia Isabel Jardim, Luís Ramos dos Santos, Inês Araújo, Filipa Marques, Patrícia Branco, Augusta Gaspar, Cândida Fonseca   +6 more
doaj   +1 more source

A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting

ESC Heart Failure, EarlyView.
Abstract Aims There is growing recognition of the burden and prognostic significance of WHF treated in the outpatient setting. However, there is currently a lack of prospective real‐world data in this area of HF care. This study aims to analyse the natural history of outpatient WHF.
Joseph McCambridge, Fiyinfoluwa Fabamwo, Shadia Taha, Dermot McCaffrey, Matthew Barrett, Ciara Mahon, Kenneth McDonald   +6 more
wiley   +1 more source

The role of urine sodium in acutely decompensated heart failure

International Journal of Cardiology: Heart & Vasculature
Background: Diuretic resistance is common and results in poor outcome. Spot urine sodium (UrNa) is suggested as a tool to tailor diuretics and improve efficacy of therapy. We prospectively evaluate the prevalence of diuretic resistance, predictors of low
Mick Hoen, Delian E Hofman, Bjorn H.A. Hompes, Lukas E.E. Peeters, Bart Langenveld, Roland R.J. van Kimmenade, Leon A.M. Frenken, Timo Lenderink, Hans-Peter Brunner-La Rocca, Sandra Sanders-Van Wijk   +9 more
doaj   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

ESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz, Francesco Fioretti, Sara Ladak, Mohammed Obaidan, Javed Butler, Aamir Hameed   +5 more
wiley   +1 more source

Decongestion: Diuretics and other therapies for hospitalized heart failure

Indian Heart Journal, 2016
Acute heart failure (AHF) is a potentially life-threatening clinical syndrome, usually requiring hospital admission. Often the syndrome is characterized by congestion, and is associated with long hospital admissions and high risk of readmission and ...
Ali Vazir, Martin R. Cowie
doaj   +1 more source

A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction

ESC Heart Failure, EarlyView.
The QUAD score was developed to promote adherence to clinical practice guidelines for patients with heart failure and a reduced left ventricular ejection fraction <50%. In newly diagnosed patients who had completed therapy titration, we found that patients with an excellent QUAD score had a significant reduction in the risk of mortality or ...
Henry Oluwasefunmi Savage, Jason N. Dungu, Anthony Dimarco, Brian Li, Samantha Langley, Jonathan Kojo Amoah, Paraic Cliffe, Archana Ganapathy, Peter Watters, Patricia Campbell, Nicola Melarkey, Simon Duckett, Sean Davies, Matthew Dewhurst, Karen Hann, Louise Clayton, Rhys Williams, Victoria Ruszala, Teresa Onwere‐Tan, Fozia Zahir Ahmed, Ibrahim Arosi, Kimberly Gray, Mark C. Petrie, John G.F. Cleland   +23 more
wiley   +1 more source